Synodos for NF2 Consortium publishes key results of its workJune 14, 2018
The Synodos for NF2 consortium of the Children's Tumor Foundation (CTF) today published its first set of results and released its second set of data in the leading scientific journal PLOS ONE. Synodos is the Foundation's innovative team science collaborative that brings researchers, clinicians and patients together in a shared data environment, in order to develop treatments for NF patients at an accelerated pace. Established in 2014, the $3 million project is a combined effort among 12 leading research labs at 8 institutions.
The Synodos for NF2 team released its first set of results and data in the scientific journal PLOS ONE, entitled Traditional and Systems Biology Based Drug Discovery for the Rare Tumor Syndrome Neurofibromatosis Type 2. In line with the Foundation's principles of open-access and data sharing, the journal is making the full article available to all, with immediate access to the data.
The primary aim of the Synodos for NF2 team was to find treatments that could be used for both meningioma and schwannoma by using a drug discovery approach of selecting mechanistically relevant compounds. The team integrated innovative research approaches such as Next Generation Sequencing (NGS) and Kinome profiling. These two techniques allow analysis of the alteration in expression of genes and proteins in cells or animal models.
A core finding was that while schwannomas and meningiomas are both initiated by merlin loss, the distinctly different responses to that loss of function are likely to prescribe that a single drug (target) is unlikely to be optimally effective in both cell types. Instead, it is likely that different drugs or combos (a cocktail of two or more drugs) aimed at distinct targets will be required to treat these two tumor types. In fact, the first three single drugs tested (Panobinostat, CUDC-907 and GSK2126458) were only mildly active in preventing tumors from growing. The next set of experiments started looking at drug combinations and the team reported that the drug Dasatininb, a multi-kinase inhibitor in combination with AZD-2014 or INK128, both dual mTORC1/2 inhibitors, suppressed tumor growth up to ~85% in a meningioma animal model (this last result was reported earlier in March 2018 by the Synodos team in the scientific journal Neuro-Oncology. That publication can be found here: https://doi.org/10.1093/neuonc/noy046).
Additionally, the work of the Synodos for NF2 consortium has filled a critical gap in the understanding of how the NF2 mutation and the absence of merlin influence tumor cell behavior in both meningiomas and schwannomas. The collective effort of twelve research groups succeeded in:
- (1) creating a new pipeline of well-validated tools for NF2-associated drug discovery with fully characterized isogenic pairs of meningioma and schwannoma cell systems;
(2) gaining conceptual insights into disease mechanisms via transcriptome and kinome interrogation that indicate that different drugs are likely to be needed to treat meningioma and schwannoma;
(3) validating pathways and targets that are altered based on tumor type and in response to targeted pathway inhibition in the setting of NF2; and
(4) building an openly accessible database for community sharing and mining of drug treatment, transcriptome and kinome data from isogenic schwannoma and meningioma cell systems. This data presents several targets to consider for single agent and combination therapy in the short term, and provides a deep and rich open access data resource for the broader research community seeking treatments for NF2-associated meningioma and schwannoma for the long term.
Ultimately, these newly released results and data are providing, for the first time, a critical resource that will be invaluable to the NF2 research community. This work illustrates that the CTF model of bringing together scientists of diverse expertise areas improves the ability to discover new therapeutic strategies to treat these highly devastating tumors.
The full article in PLOS ONE can be found here: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197350
The Children's Tumor Foundation is a 501(c)(3) not-for-profit organization dedicated to funding and driving innovative research that will result in effective treatments for the millions of people worldwide living with neurofibromatosis (NF), a term for three distinct disorders: NF1, NF2, and schwannomatosis. NF causes tumors to grow on nerves throughout the body and may lead to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, and cancer. NF affects 1 in every 3,000 births across all populations equally. There is no cure yet - but the Children's Tumor Foundation mission of driving research, expanding knowledge, and advancing care for the NF community fosters our vision of one day ending NF. For more information, please visit http://www.ctf.org.
Vice President, Marketing and Communications
Children's Tumor Foundation
Children's Tumor Foundation
Related Drug Discovery Articles:
Researchers from Kyoto University, MIT, and ETH Zurich have developed a compact drug discovery method using simple models and small data sets.
A research team from the Virginia Tech Center for Drug Discovery has received a $431,126 two-year grant from the National Institutes of Health to make improved versions of a promising compound called MMV008138, or 8138 for short.
A new computational tool called fABMACS is helping scientists see beyond static images of proteins to more efficiently understand how these molecules function, which could ultimately speed up the drug discovery process.
When treated with an anti-cancer drug, ICRF-193, fission yeast produce an 'arched and snapped' phenotype that may be used to screen for other cancer drugs.
In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria as well as cancer.
The biopharmaceutical company Celgene has become the fifth company to join the 'Neglected Tropical Diseases Drug Discovery Booster' consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world's most neglected diseases, leishmaniasis and Chagas disease.
Researchers at the Institute for Systems Biology and Center for Infectious Disease Research in Seattle have deciphered how the human pathogen Mycobacterium tuberculosis is able to tolerate the recently approved FDA drug bedaquiline.
Scientists from Insilico Medicine in collaboration with Datalytic Solutions and Mind Research Network trained deep neural networks to predict the therapeutic use of large number of multiple drugs using gene expression data obtained from high-throughput experiments on human cell lines.
A new drug discovery approach has yielded a potential therapy for breast cancer that may be more effective than existing medicines.
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods.
Related Drug Discovery Reading:
Drugs: From Discovery to Approval
by Rick Ng (Author)
The third edition of this best-selling book continues to offer a user-friendly, step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of pre-clinical studies, the conduct of human clinical trials, regulatory controls, and even the manufacturing processes for pharmaceutical products.Concise and easy to read, Drugs: From Discovery to Approval, Third Edition quickly introduces basic concepts, then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs. The... View Details
Basic Principles of Drug Discovery and Development
by Benjamin Blass (Author)
Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, providing comprehensive explanations of enabling technologies such as high throughput screening, structure based drug design, molecular modeling, pharmaceutical profiling, and translational medicine, all areas that have become critical steps in the successful development of marketable therapeutics.
The text introduces the fundamental principles of drug discovery and development, also discussing important drug targets by class, in vitro screening... View Details
Drug Discovery and Development: Technology in Transition, 2e
by Raymond G Hill (Editor)
The modern pharmacopeia has enormous power to alleviate disease, and owes its existence almost entirely to the work of the pharmaceutical industry. This book provides an introduction to the way the industry goes about the discovery and development of new drugs. The first part gives a brief historical account from its origins in the mediaeval apothecaries’ trade, and discusses the changing understanding of what we mean by disease, and what therapy aims to achieve, as well as summarising case histories of the discovery and development of some important drugs. The second part focuses on the... View Details
Drug Discovery: From Bedside to Wall Street
by Tamas Bartfai (Author), Graham V. Lees (Author)
Everyone expects something from the drug industry. Physicians and patients, investors, regulators and administrators all have an active interest. Everyone wants to know what makes drugs ‘work’ medically and economically. Why are drugs so expensive? Is it the drug companies or investors who demand high profits? What governs the pharmacoeconomics? Why are so few diseases treatable?
Drug Discovery opens the windows and doors of the industry telling the story of drug development by using real stories from inside the process.Co-written by Graham Lees and Tamas Bartfai who... View Details
Bioinformatics and Computational Biology in Drug Discovery and Development
by William T. Loging (Editor)
Computational biology drives discovery through its use of high-throughput informatics approaches. This book provides a road map of the current drug development process and how computational biology approaches play a critical role across the entire drug discovery pipeline. Through the use of previously unpublished, real-life case studies the impact of a range of computational approaches are discussed at various phases of the pipeline. Additionally, a focus section provides innovative visualisation approaches, from both the drug discovery process as well as from other fields that utilise large... View Details
Drug Discovery: Practices, Processes, and Perspectives
by Jie Jack Li (Editor), E. J. Corey (Editor)
Sets forth the history, state of the science, and future directions of drug discovery
Edited by Jie Jack Li and Nobel laureate E. J. Corey, two leading pioneers in drug discovery and medicinal chemistry, this book synthesizes great moments in history, the current state of the science, and future directions of drug discovery into one expertly written and organized work. Exploring all major therapeutic areas, the book introduces readers to all facets and phases of drug discovery, including target selection, biological testing, drug metabolism, and computer-assisted drug... View Details
Drug Discovery: A History
by Walter Sneader (Author)
Written by a leading authority with an excellent reputation and ability for writing a good narrative, Drug Discovery: A History is a far cry from simply a list of chemical structures.
This lively new text considers the origins, development and history of medicines that generate high media interest and have a huge social and economic impact on society.
Set within a wide historical, social and cultural context, it provides expanded coverage of pre-twentieth century drugs, the huge advances made in the twentieth century and the latest developments in drug research.... View Details
Peptide-based Drug Discovery: Challenges and New Therapeutics
by Ved Srivastava (Editor), David Thurston (Editor), David Rotella (Editor), Tomi Sawyer (Editor), Andrew Young (Editor), David Sabatino (Editor), Colette Dooley (Editor), Andrei Yudin (Editor), Gangadar J. Sanjayan (Editor), Jane V Aldrich (Editor), Shane Roller (Editor), Ram Dharanipragada (Editor), Kit Lam (Editor), Kamala Kesavan (Editor), Elisabetta Bianchi (Editor), Victor J. Hruby (Editor), Chengzao Sun (Editor), Om Prakash (Editor), Nozer Mehta (Editor), Paul Watt (Editor), Fernando Albericio (Editor)
With potentially high specificity and low toxicity, biologicals offer promising alternatives to small-molecule drugs. Peptide therapeutics have again become the focus of innovative drug development efforts backed up by a resurgence of venture funds and small biotechnology companies.
What does it take to develop a peptide-based medicine? What are the key challenges and how are they overcome? What are emerging therapeutics for peptide modalities? This book answers these questions with a holistic story from molecules to medicine, combining the themes of design, synthesis and... View Details
Anticancer Therapeutics: From Drug Discovery to Clinical Applications
by Adam Todd (Author), Paul W. Groundwater (Author), Jason H. Gill (Author)
An integrated presentation of the basic science and clinical applications of anticancer agents
Aimed at both undergraduate and postgraduate readers, this unique text provides readers with a fully-integrated presentation of all aspects of the science of anticancer drugs, including their chemistry, pharmacology, and clinical applications.
After heart disease, cancer is the number one killer worldwide, and the tumor microenvironment is forever changing, creating an ever-greater demand for safer, more effective anticancer agents. In response to that demand, the $100... View Details
High Price: A Neuroscientist's Journey of Self-Discovery That Challenges Everything You Know About Drugs and Society (P.S.)
by Carl Hart (Author)
High Price is the harrowing and inspiring memoir of neuroscientist Carl Hart, a man who grew up in one of Miami’s toughest neighborhoods and, determined to make a difference as an adult, tirelessly applies his scientific training to help save real lives.
Young Carl didn't see the value of school, studying just enough to keep him on the basketball team. Today, he is a cutting-edge neuroscientist—Columbia University’s first tenured African American professor in the sciences—whose landmark, controversial research is redefining our understanding of addiction.